Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to ...

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

An Eli Lilly & Co. Zepbound injection pen in Brooklyn ... Zepbound is a medication containing tirzepatide, which the preliminary study showed to be more effective for weight loss than Wegovy ...

2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound ® (tirzepatide) provided a 47% ...

Zepbound, a drug with the main active ingredient tirzepatide ... Wegovy during the 72-week trial. PHOTO: An Eli Lilly & Co. Zepbound injection pen in Brooklyn, N.Y, March 28, 2024.

Eli Lilly (NYSE: LLY ... that have been prescribed for a billion-dollar indication: weight loss. Lilly makes tirzepatide, which is approved for type 2 diabetes under the name Mounjaro and for ...